Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will New Antibiotic Incentives GAIN Investors’ Backing?

Executive Summary

The GAIN Act is intended to spur development of new antibiotics, but incentives like extended market exclusivity and priority review, while important benefits, may not be enough to get investors off the sidelines.

You may also be interested in...



Cellceutix Buys Mid-Stage Antibiotic Brilacidin On The Cheap

With brilacidin developer PolyMedix having filed for bankruptcy, Cellceutix will acquire the company’s assets for $2.1 million in cash and 1.4 million shares of stock.

Seeking Funds For Phase III Antibiotic, Paratek Files For IPO

The Boston-based drug developer believes it has resolved the regulatory issues that led to the dissolution of a partnership with Novartis around the drug omadacycline.

Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity

Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel